Updates

Author Details

Joe Pierce

August 12, 2020August 12, 2020
XPro1595 Lowers Neuroinflammation in Mild to Moderate Alzheimer’s, Interim Results Show

XPro1595, an investigational therapy by INmune Bio, can lower brain inflammation in people with mild to moderate Alzheimer’s disease, according to interim results of ... Read more
August 10, 2020August 6, 2020
Young People May Exhibit Risks Associated With Alzheimer’s Disease, Research Finds

This year’s Alzheimer’s Association International Conference (AAIC) revealed surprising news about risk factors related to Alzheimer’s, adolescents, young adults, and diagnosis. For years, researchers ... Read more
August 10, 2020August 10, 2020
Aducanumab Wins FDA Priority Review, Moves Closer to US Approval

The U.S. Food and Drug Administration (FDA) has accepted and given priority review designation to Biogen‘s application requesting the approval of aducanumab (BIIB037) for the treatment ... Read more
August 5, 2020August 5, 2020
Rare Disease Communities Invited to Submit Works to 2020 Rare Artist Contest

To raise awareness of the rare disease communities and celebrate the creativity of its members, the EveryLife Foundation for Rare Diseases is seeking submissions ... Read more
August 3, 2020July 30, 2020
Why an Aging Population Might Not Exercise

Physical exercise plays a significant role in defense against Alzheimer’s disease, according to an article from Biomedical Reports. Aging is a cognitive impairment risk ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Author Details

Joe Pierce

Thanks! Please check your email for a confirmation email.

November 8, 2017November 8, 2017

Anavex ‘Cautiously Optimistic’ After Noting Cognitive Improvement in Alzheimer’s Treatment

News

Anavex Life Sciences says its Alzheimer’s drug candidate Anavex 2-73 may have a role in treating the disease. Data from a long-term extension trial, although small, indicated that the therapy improved cognitive and functional measures in patients. According to data ... Read more

XPro1595 Lowers Neuroinflammation in Mild to Moderate Alzheimer’s, Interim Results Show

Young People May Exhibit Risks Associated With Alzheimer’s Disease, Research Finds

Aducanumab Wins FDA Priority Review, Moves Closer to US Approval

Rare Disease Communities Invited to Submit Works to 2020 Rare Artist Contest

Why an Aging Population Might Not Exercise

Trial of Potential Alzheimer’s Vaccine Advances to Medium Dose Group

People With Alzheimer’s Disease Often Resist Loss of Control

Flu, Pneumonia Vaccinations Linked to Reduced Risk of Alzheimer’s, Researchers Say

FDA to Consider Nuplazid to Treat Dementia-related Psychosis

Care Facilities Lockdown Is Hard on Parents with Dementia

Global Phase 3 Trial Will Test BAN2401 in Early-stage Asymptomatic Alzheimer’s

Subscribe to our mailing list

Alzheimer’s Foundation Expands Toll-free Helpline to Support Patients, Caregivers

Will Alzheimer’s Disease Affect Voter Turnout by Seniors?

Biogen, Eisai Seek FDA Approval of Aducanumab for Alzheimer’s

Foundation Offers Free Online Memory Screenings

Caregiving Is a Judgment-free Zone

AlzeCure Announces Positive Data From Its First Clinical Study of ACD856

Amylyx Completes Enrollment in PEGASUS Trial of AMX0035 for Alzheimer’s

Simple Solutions to Everyday Caregiving Challenges

Investigational Agitation Treatment AXS-05 Named FDA Breakthrough Therapy

Advanced Imaging Captures Protein Clumps in Neurons at Early Alzheimer Stages

Father’s Day Prompts Memories of My Mom’s Dementia Diagnosis

Amyloid Clumps Formed on Space Station Affected by Microgravity

Anavex 2-73 Trial for Early Alzheimer’s Expanded to Canada, UK

Let’s Use Alzheimer’s and Brain Awareness Month to Eliminate Brain Freeze

Neurotrope Launches Long-term Trial of Bryostatin-1

Alzheimer’s Disease: A Defense in Scary Times

‘The Longest Day’ Global Fundraiser Set for June 20

Mouth Bacteria Can Infect Brain Cells, Research Finds, Supporting Alzheimer’s Link

Helpful Steps Following a Dementia Diagnosis

FDA Approves Tauvid as First Tau Protein Tracer Tool for Alzheimer’s Diagnosis

Visiting a Loved One with Dementia Requires a Delicate Balance

PTI-125 Fails to Lower Alzheimer’s Protein Levels in Phase 2 Trial

Maintaining Brain Health Is Important for Future Cognitive Function

Potential Agitation Treatment, AXS-05, Shows Efficacy and Safety in Phase 2/3 Trial

Large Study Finds No Evidence That Low-dose Aspirin Reduces Alzheimer’s Risk

Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak

Alzheimer’s Caregivers Often Fear Contracting the Disease

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

FDA Filing of Alzheimer’s Therapy Aducanumab Delayed to Late 2020, Biogen Says

Anticipating Summer Solstice in Support of Alzheimer’s Funding

Lundbeck Sharing Data on Failed Idalopirdine Trials with Scientists via C-Path

Pin It on Pinterest